Caerus Investment Advisors LLC Takes Position in Incyte Corporation

Hedge fund acquires new stake in biopharmaceutical company

Mar. 18, 2026 at 8:52am

Got story updates? Submit your updates here. ›

Caerus Investment Advisors LLC acquired a new position in shares of Incyte Corporation (NASDAQ:INCY) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,817 shares of the biopharmaceutical company's stock, valued at approximately $663,000.

Why it matters

This investment by Caerus Investment Advisors reflects growing institutional interest in Incyte Corporation, a leading biopharmaceutical firm focused on oncology and inflammation therapies. Incyte's flagship product is the JAK inhibitor Jakafi, approved for the treatment of myelofibrosis and polycythemia vera.

The details

Several other hedge funds have also recently added to or reduced their stakes in INCY. Harbor Capital Advisors Inc. acquired a new position in Incyte during the 3rd quarter, and a number of other firms have adjusted their positions in the stock in recent quarters.

  • Caerus Investment Advisors acquired the new position in Incyte in the third quarter of 2025.

The players

Caerus Investment Advisors LLC

An investment management firm that acquired a new stake in Incyte Corporation.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Incyte's flagship product is the JAK inhibitor Jakafi.

Got photos? Submit your photos here. ›

The takeaway

This investment by Caerus highlights the growing institutional interest in Incyte as a leader in the biopharmaceutical space, particularly as the company continues to advance its pipeline of innovative oncology and inflammation therapies.